Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe …
Dec 1, 2025 · To evaluate the efficacy of combination lipid-lowering therapy (LLT) compared with statin monotherapy for low-density lipoprotein cholesterol (LDL-C) …
Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe …
Dec 1, 2025 · To evaluate the efficacy of combination lipid-lowering therapy (LLT) compared with statin monotherapy for low-density lipoprotein cholesterol (LDL-C) reduction, associated adverse events, …
efficacy of dual lipid-lowering therapy with ezetimibe and statin on ...
Nov 5, 2025 · This meta-analysis evaluates whether the combination of ezetimibe and statin offers superior coronary plaque volume regression compared with statin monotherapy in patients following …
Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus ...
Apr 5, 2024 · The latest research on cardiovascular risk reduction suggests that coupling low-moderate dose statin therapy with ezetimibe may be a highly effective therapy. In this analysis, we have …
May 24, 2025 · Eficacy and Safety of Moderate-Intensity Statin and Ezetimibe Combination Therapy Versus High-Intensity Statin Monotherapy in Patients With Cardiovascular Disease:
Nonstatin therapy to reduce low-density lipoprotein cholesterol and ...
Jan 1, 2024 · This review addresses the indications, evidence, and important prescribing considerations for using nonstatin lipid-lowering therapy and proposes a practical approach for determining when to …
Lipid-lowering therapy. What comes after the standard treatment ...
Mar 5, 2024 · Summary Low-density lipoprotein cholesterol (LDL-C) continues to be the main target of hypolipidaemic treatment, aiming for levels as low as <55 mg/dl in secondary prevention. As the …
Adding ezetimibe to PCSK9 inhibitor and statins did not reduce outcomes beyond MID, while adding PCSK9 inhibitor to ezetimibe and statins may reduce stroke (13 per 1000). These effects were …
Efficacy and safety of lipid-lowering therapies in combination with or ...
Dec 1, 2024 · Cardiovascular diseases (CVD) pose a significant global health burden. Lowering low-density lipoprotein-cholesterol is the primary therapeutic aim for…
Choosing the optimal nonstatin lipid-lowering therapies for statin ...
Sep 1, 2025 · Cardiovascular diseases (CVDs) are a leading cause of morbidity and mortality globally, with elevated low-density lipoprotein cholesterol (LDL-C) as a major risk factor. 1,2 Statins, the first …